No annual revenue total was found in OLEMA PHARMACEUTICALS, INC.'s SEC filings.
Olema Pharmaceuticals, Inc. (OLMA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $461.1 million in cash and investments and $660,000 in total debt.
Revenue
—
Net income (TTM)
$-204.57M
-43.8% vs year-ago TTM
Operating cash flow (TTM)
$-164.74M
-29.5% vs year-ago TTM
Free cash flow (TTM)
$-165.12M
EPS (TTM)
$-2.13
-9.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
87.16M
+27.5% vs prior year
Net cash
$460.41M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OLMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1750284
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$178.7M | -$142.3M | -$105.0M | -$107.0M | -$71.5M |
| Net income | -$162.5M | -$129.5M | -$96.7M | -$104.8M | -$71.1M |
| Diluted EPS | -$1.87 | -$2.20 | -$2.14 | -$2.62 | -$1.80 |
| Operating cash flow | -$146.7M | -$104.4M | -$83.7M | -$82.1M | -$50.7M |
| Free cash flow | — | -$104.5M | — | -$82.4M | -$52.3M |
| Total assets | $533.4M | $451.0M | $276.9M | $215.6M | $295.9M |
| Total liabilities | $54.9M | $42.0M | $23.1M | $18.1M | $11.4M |
| Stockholders' equity | $478.6M | $409.0M | $253.9M | $197.5M | $284.6M |
| Cash and investments | $505.4M | $434.1M | $261.8M | $204.4M | $287.2M |
| Total debt | $1.2M | $1.4M | $2.4M | $2.6M | $3.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 15, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 26, 2026 | May 26, 2026 |
All 562 Olema Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.